309 related articles for article (PubMed ID: 18245487)
1. Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3.
Ishii Y; Waxman S; Germain D
Cancer Res; 2008 Feb; 68(3):852-60. PubMed ID: 18245487
[TBL] [Abstract][Full Text] [Related]
2. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model.
Ishii Y; Pirkmaier A; Alvarez JV; Frank DA; Keselman I; Logothetis D; Mandeli J; O'Connell MJ; Waxman S; Germain D
J Natl Cancer Inst; 2006 Sep; 98(17):1238-47. PubMed ID: 16954476
[TBL] [Abstract][Full Text] [Related]
3. Cyclin D1 expression is dependent on estrogen receptor function in tamoxifen-resistant breast cancer cells.
Kilker RL; Hartl MW; Rutherford TM; Planas-Silva MD
J Steroid Biochem Mol Biol; 2004 Sep; 92(1-2):63-71. PubMed ID: 15544931
[TBL] [Abstract][Full Text] [Related]
4. Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3.
Leslie K; Lang C; Devgan G; Azare J; Berishaj M; Gerald W; Kim YB; Paz K; Darnell JE; Albanese C; Sakamaki T; Pestell R; Bromberg J
Cancer Res; 2006 Mar; 66(5):2544-52. PubMed ID: 16510571
[TBL] [Abstract][Full Text] [Related]
5. Cyclin D1 expression and patient outcome after tamoxifen therapy in estrogen receptor positive metastatic breast cancer.
Han S; Park K; Bae BN; Kim KH; Kim HJ; Kim YD; Kim HY
Oncol Rep; 2003; 10(1):141-4. PubMed ID: 12469160
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer.
Kenny FS; Hui R; Musgrove EA; Gee JM; Blamey RW; Nicholson RI; Sutherland RL; Robertson JF
Clin Cancer Res; 1999 Aug; 5(8):2069-76. PubMed ID: 10473088
[TBL] [Abstract][Full Text] [Related]
7. Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids.
Selvendiran K; Koga H; Ueno T; Yoshida T; Maeyama M; Torimura T; Yano H; Kojiro M; Sata M
Cancer Res; 2006 May; 66(9):4826-34. PubMed ID: 16651438
[TBL] [Abstract][Full Text] [Related]
8. Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells.
Behera R; Kumar V; Lohite K; Karnik S; Kundu GC
Carcinogenesis; 2010 Feb; 31(2):192-200. PubMed ID: 19926637
[TBL] [Abstract][Full Text] [Related]
9. Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance.
Ahnström M; Nordenskjöld B; Rutqvist LE; Skoog L; Stål O
Breast Cancer Res Treat; 2005 May; 91(2):145-51. PubMed ID: 15868442
[TBL] [Abstract][Full Text] [Related]
10. EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity.
Lu M; Miller KD; Gokmen-Polar Y; Jeng MH; Kinch MS
Cancer Res; 2003 Jun; 63(12):3425-9. PubMed ID: 12810680
[TBL] [Abstract][Full Text] [Related]
11. Dietary flaxseed interaction with tamoxifen induced tumor regression in athymic mice with MCF-7 xenografts by downregulating the expression of estrogen related gene products and signal transduction pathways.
Chen J; Power KA; Mann J; Cheng A; Thompson LU
Nutr Cancer; 2007; 58(2):162-70. PubMed ID: 17640162
[TBL] [Abstract][Full Text] [Related]
12. Cyclin D-1, interleukin-6, HER-2/neu, transforming growth factor receptor-II and prediction of relapse in women with early stage, hormone receptor-positive breast cancer treated with tamoxifen.
Muss HB; Bunn JY; Crocker A; Plaut K; Koh J; Heintz N; Rincon M; Weaver DL; Tam D; Beatty B; Kaufman P; Donovan M; Verbel D; Weiss L
Breast J; 2007; 13(4):337-45. PubMed ID: 17593037
[TBL] [Abstract][Full Text] [Related]
13. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
Lee A; Park WC; Yim HW; Lee MA; Park G; Lee KY
Jpn J Clin Oncol; 2007 Sep; 37(9):708-14. PubMed ID: 17940078
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
Chang SB; Miron P; Miron A; Iglehart JD
J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
[TBL] [Abstract][Full Text] [Related]
15. EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival.
Hui R; Ball JR; Macmillan RD; Kenny FS; Prall OW; Campbell DH; Cornish AL; McClelland RA; Daly RJ; Forbes JF; Blamey RW; Musgrove EA; Robertson JF; Nicholson RI; Sutherland RL
Oncogene; 1998 Aug; 17(8):1053-9. PubMed ID: 9747885
[TBL] [Abstract][Full Text] [Related]
16. Cyclin d1 overexpression sensitizes breast cancer cells to fenretinide.
Pirkmaier A; Yuen K; Hendley J; O'Connell MJ; Germain D
Clin Cancer Res; 2003 May; 9(5):1877-84. PubMed ID: 12738746
[TBL] [Abstract][Full Text] [Related]
17. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.
Aesoy R; Sanchez BC; Norum JH; Lewensohn R; Viktorsson K; Linderholm B
Mol Cancer Res; 2008 Oct; 6(10):1630-8. PubMed ID: 18922978
[TBL] [Abstract][Full Text] [Related]
18. [Significance of phosphorylation of mitogen-activated protein kinase and signal transducer and activator of transcription 3 and cyclin D1 protein expression in Hodgkin's lymphomas].
Luo HY; Wang HC; Li YN; Zheng H
Ai Zheng; 2003 Mar; 22(3):266-9. PubMed ID: 12654183
[TBL] [Abstract][Full Text] [Related]
19. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification.
Jirström K; Stendahl M; Rydén L; Kronblad A; Bendahl PO; Stål O; Landberg G
Cancer Res; 2005 Sep; 65(17):8009-16. PubMed ID: 16140974
[TBL] [Abstract][Full Text] [Related]
20. G-quartet oligonucleotides: a new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis.
Jing N; Li Y; Xiong W; Sha W; Jing L; Tweardy DJ
Cancer Res; 2004 Sep; 64(18):6603-9. PubMed ID: 15374974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
